The global antidepressant and Anti-anxiety drugs market is estimated to have reached $12.16bn in 2018. In 2018, the SSRIs segment held 26% of the global antidepressant and anti-anxiety drugs market.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 213-page report you will receive 73 tables and 92 figures– all unavailable elsewhere.
The 213-page report provides clear detailed insight into the global antidepressant and anti-anxiety drugs market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
Global antidepressant and anti-anxiety drugs market forecasts from 2019-2029
Our investigation shows forecasts to 2029 for the following submarket by drug class:
- Serotonin Reuptake Inhibitors (SSRIs)
- Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
- Atypical Antipsychotics
- Tricyclic Antidepressants (TCAs)
- Serotonin Antagonist and Reuptake Inhibitors (SARIs)
- Benzodiazepines
- Monoamine Oxidase Inhibitors (MAOIs)
- Others
Our investigation shows forecasts to 2029 for the following submarket by indication:
- Major Depressive Disorder (MDD)
- General Anxiety Disorder (GAD)
- Panic Disorder (PD)
- Obsessive Compulsive Disorder (OCD)
- Others
Our investigation shows forecasts to 2029 for the selected leading drugs:
- Abilify
- Abilify Maintena
- Brintellix/Trintellix
- Cipralex/Lexapro
- Cymbalta
- Invega Sustenna/ Xeplion/Trinza/Trevicta
- Lamictal
- Rexulti
- Risperdal Consta
- Zyprexa
This report provides individual revenue forecasts to 2029 for these regional and national markets:
- North America: the US, Canada
- Europe: the UK, Germany, Spain, France, Italy, Russia, Rest of Europe
- Asia-Pacific: Japan, China, India, South Korea, Rest of Asia-Pacific
- RoW: Brazil, Mexico, Russia, South Africa, Rest of RoW
This report also provides discussion and qualitative analysis on:
- Factors that drive and restrain the global antidepressant and Anti-anxiety drugs market.
- Antidepressant drugs pipeline analysis
- Anti-anxiety drugs pipeline analysis
This report discusses the selected leading companies:
- Allergan plc.
- AstraZeneca plc.
- Eli Lilly and Company
- GlaxoSmithKline plc.
- H. Lundbeck A/S
- Johnson & Johnson
- Otsuka Pharmaceutical Co., Ltd.
- Pfizer Inc.
- Pfizer Inc.
- Takeda Pharmaceutical Company Ltd.
- Valeant Pharmaceuticals